While biopharma share prices dived recently after President-elect Donald Trump promised to let Robert F. Kennedy Jr. “go wild” in reforming government health programs, a senior US Food and Drug Administration leader has sought to reassure that the agency will not be undermined.
Marks Believes Trump Team Won’t Threaten US FDA’s Medicines Expertise
The US FDA’s Peter Marks told the Jefferies meeting that the agency’s scientific leadership will be protected, and said it wants to do more to help the sector accelerate innovation.
More from Leadership
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.